高级检索
当前位置: 首页 > 详情页

Comprehensive characterization of B7 family members in NSCLC and identification of its regulatory network

文献详情

资源类型:
Pubmed体系:
机构: [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, People’s Republic of China. [2]South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, People’s Republic of China. [3]Sichuan Clinical Research Center for Birth Defects, Luzhou, Sichuan, People’s Republic of China. [4]Department of Obstetrics, Affiliated Hospital of Southwest Medical University, Luzhou, People’s Republic of China. [5]Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People’s Republic of China. [6]Department of Oncology and Hematology, Hospital (T.C.M) Affiliated to Southwest Medical University, Luzhou, Sichuan, People’s Republic of China. [7]Department of Pharmacy, University-Town Hospital of Chongqing Medical University, Chongqing, People’s Republic of China.
出处:

摘要:
B7 family members act as co-stimulatory or co-inhibitory molecules in the adaptive immune system. Thisstudy aimed to investigate the dysregulation, prognostic value and regulatory network of B7 family members in non-small cell lung cancer (NSCLC). Data for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients were extracted from public databases. Patient prognosis was determined by Kaplan-Meier analysis. The downstream signaling pathways of B7 family were identified via GO and KEGG analysis. The key B7 related genes were selected by network, correlation and functional annotation analysis. Most B7 family members were dysregulated in LUAD and LUSC. The expression of B7-1/2/H3 and B7-H5 were significantly associated with overall survival in LUAD and LUSC, respectively. The major pathway affected by B7 family was the EGFR tyrosine kinase inhibitor resistance and ErbB signaling pathway. MAPK1, MAPK3 and MAP2K1 were pivotal B7 related genes in both LUAD and LUSC. This study reveals an overall dysregulation of B7 family members in NSCLC and highlights the potential of combination use of tyrosine kinase inhibitors or MEK/ERK inhibitors with B7 member blockade for NSCLC treatment.© 2023. The Author(s).

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 2 区 综合性期刊
小类 | 2 区 综合性期刊
最新[2023]版:
大类 | 2 区 综合性期刊
小类 | 2 区 综合性期刊
第一作者:
第一作者机构: [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, People’s Republic of China. [2]South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, People’s Republic of China.
共同第一作者:
通讯作者:
通讯机构: [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, People’s Republic of China. [2]South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, People’s Republic of China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:52808 今日访问量:2 总访问量:4561 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号